Introduction
Somatostatin and its analogs have been shown to exert an antiproliferative action on different cell lines (Motta & Serio 1994 , Cheung & Boyages 1995 , Reubi & Laissue 1995 , Yoshitomi et al. 1997 . In particular, somatostatin has been demonstrated to inhibit directly the proliferation of the human prostatic cancer cell line, LNCaP (Lymph Node Carcinoma of the Prostate), and to induce a significant decrease in the proteins secreted by these cells (Brevini et al. 1993) . The possibility of a functional link between the antiproliferative and the antisecretory actions of somatostatin has been suggested since, at least in LNCaP cells, both effects appear to involve tyrosine dephosphorylation processes (Brevini et al. 1993) . Several growth stimulatory factors -epidermal growth factor (EGF), transforming growth factor α (TGFα), and basic fibroblast growth factor -are involved in the control of prostatic cancer growth (Schuurmans et al. 1991 , Ching et al. 1993 , Limonta et al. 1994 , possibly acting via the intracellular activation of tyrosine kinases (Cooper & Hunter 1984 , Gill 1990 ). Based on these observations, we have focussed our attention on the possibility that somatostatin might inhibit LNCaP cell growth by affecting phoshorylation processes connected with growth factor actions. Specifically, the interactions of somatostatin with the EGF/TGFα receptor family of tyrosine kinases have been considered. Moreover, the possibility that somatostatin might interfere with the release of ligands, possibly involved in an autocrine/paracrine activation of such a receptor has been investigated. To this purpose, the following experiments have been performed: (a) study of the possible interactions of somatostatin with the phosphorylation of the EGF/TGFα receptor in LNCaP cells; (b) analysis of the possible interactions of somatostatin with the activation of phosphotyrosine phosphatases (PTPs); (c) evaluation of the interactions of somatostatin with the secretion of factors, such as TGFα, possibly acting as endogenous ligands for the EGF/TGFα receptor. 
Materials and methods

Cell culture
The cell line LNCaP was obtained from the American Type Culture Collection (Rockville, MD, USA). Cells were cultured as previously described (Horoszewics et al. 1983) . All studies were performed on exponentially growing cells which were then treated according to the experiments described in the following sections. Unless otherwise indicated, somatostatin was used at a concentration of 1 nM, since this dose has been demonstrated to exert potent antiproliferative and antisecretory effects on LNCaP cells (Brevini et al. 1993) . incubated in the same medium plus 100 mCi/ml [ 32 P]orthophosphate (specific activity 370 MBq/ml) and treated with conditioned medium (CM) or TGFα (10 ng/ml) in the presence or absence of somatostatin for 45 min. At the end of the incubation period, cells were lyzed and equal aliquots of phosphoproteins were incubated with 2 µg of the specific anti-EGF receptor monoclonal antibody, 2 µg of the biotinylated 2nd step antibody and 10 µg streptavidin agarose at 4°C on a rocking platform for 12 h. Immunoprecipitates were collected by centrifugation in a microcentrifuge at 2500 g for 15 min at 4 °C. Pellets were thoroughly washed with 1 ml phosphate-buffered saline (PBS) and either resuspended in PBS for trichloroacetic acid (TCA) precipitation procedures (Brevini et al. 1993) or electrophoresed on a 4-18% SDS polyacrylamide gel (SDS-PAGE) (Laemmli 1970) . Gels were stained with Coomassie Brilliant Blue G Dye and the presence of the radiolabeled EGF/TGFα receptor at 170 kDa was visualized upon exposure of the dried gels to Amersham Hyperfilm β-max at −80 °C.
The phosphorylation levels of the EGF receptor were evaluated by measuring the incorporation of [ 
Effect of somatostatin on PTP activity in LNCaP cells
LNCaP cell membranes were prepared from untreated cells as described by Pan et al. (1992) . Aliquots of 20 µg were then preincubated with different concentrations of somatostatin (0.1 nM-10 µM) for 10 min at 30 °C in a buffer comprised of 250 mM Hepes (pH 7.2), 50 mM dithiothreitol (DTT) and 25 mM EDTA. In control replicates somatostatin was omitted. To ensure specificity for PTPs, the incubation was performed in the presence of microcystin-leucine-arginine (M-LR) 20 nM, a specific inhibitor of the major serine-threonine protein phosphatases 1 and 2A. After addition of p-nitrophenylphosphate substrate, used at a concentration of 10 mM, incubation for 30 min at 30 °C was performed. The reaction was stopped with 0.9 ml 0.2 N NaOH. The absorbance of the samples was measured at 410 nm with a Jasco V-520 UV/VIS spectrophotometer.
Effect of somatostatin on the secretion of TGFα by LNCaP cells. Detection of glycosylated residues
Exponentially growing cells were incubated in serum-free medium and either untreated or treated with somatostatin for 24 h. The culture medium was assayed for protein concentration, following the method of Bradford (1976) . Proteins were electrophoresed on a 10-20% gradient SDS-PAGE (Laemmli 1970 ) and either stained with Coomassie Brilliant Blue or transferred onto nitrocellulose filters according to the method of Towbin et al. (1979) and then probed with a specific anti-TGFα antibody. The presence of immunoreactivity was revealed with immuno gold silver staining techniques.
The detection of glycosylated residues among LNCaP cell-secreted proteins was performed after collecting the culture medium. Proteins were immobilized onto nitrocellulose membranes, as described above. The presence of glycoproteins was detected with the Boehringer digoxigenin-glycan double labeling kit, following the manufacturer's instructions.
Expression of TGFα mRNA in LNCaP cells
Total RNA from exponentially growing LNCaP cells was prepared using the method of Chomczynski & Sacchi (1987) and checked for integrity (Sambrook et al. 1989) .
The oligonucleotide primers used in the experiments were designed according to known regions of human TGFα (Heining et al. 1991) . To ensure maximal specificity and sensitivity, nested oligonucleotide primers were used as follows: external: TGTTCGCTCTGGGTA TTGTG forward (nucleotides 63-82 of the human cDNA) and reverse: GGACCGACGACAGGAATAGTATG (reverse complement of nucleotides 364-383); internal: forward ACGTCCCCGCTGAGTGCAG (nucleotides 113-132) and reverse: GGTAGTGGCGGAACCACCAC (nucleotides 320-349).
A final 237 bp DNA fragment was predicted. Reverse transcription was performed using 2 µg total RNA as the template and 100 pmol of the downstream oligonucleotide in a 20 µl reaction volume. The reaction wascarried out at 41 °C for 2 h using RNAsin (20 U/reaction), AMV reverse transcriptase (7.5 U/reaction) and dNTPs (at 1 mM each, final concentration) in a buffer consisting of 670 mM TrisHCl pH 8.8, 166 mM (NH 4 ) 2 SO 4 , 4.5% Triton X-100, 2 mg/ml gelatin in the presence of 2 mM MgCl 2 . The reaction product was heated to 95 °C for 2 min prior to storage at −20 °C or immediate use in the PCR.
PCR was carried out in 35 cycles, with the following amplification profile: 95 °C (30''); 60 °C (40''); 72 °C (50'). Nested PCR was performed by taking 2 µl reaction mixture from the first round of amplification and subjecting them to a further 20 cycles of amplification in a fresh 50 µl reaction using the internal primer pair. PCR was carried out in a GeneAmp DNA Thermocycler by Perkin Elmer.
Samples were analyzed by 2% agarose gel electrophoresis in TAE buffer (Sambrook et al. 1989) . The identity of the fragment was confirmed following the enzymatic sequence analysis method by Sanger & Coulson (1975) .
Effect of LNCaP cell conditioned medium on somatostatin-treated LNCaP cells
LNCaP cell conditioned medium (CM) was assessed for the presence of growth factors, testing its ability to stimulate mitosis and DNA synthesis in LNCaP cells. To this purpose, cells were plated in 24-well dishes and allowed to grow for 7 days (Brevini et al. 1993 ). The culture medium was then changed to serum-free medium. Fifty microlitre aliquots of previously obtained untreated LNCaP cell CM (5 µg unfractionated LNCaP cell-secreted proteins) were added alone or in combination with somatostatin (1 nM). Similarly, TGFα (10 ng/ml) was used alone or together with the hormone. Serum-free medium alone was used in control replicates. Treatments were performed in the presence of 1 µCi/ml [ 3 H]thymidine, and a 36-h incubation was carried out. At the end of the labeling period, cells were TCA-precipitated and counted for radioactive content as previously described (Brown et al. 1982) .
Statistical analysis
The present data are expressed as the means±S.E. c.p.m./well and were subjected to analysis of variance by one-factor ANOVA, followed by Dunnett's test (Dunnett 1955) . Groups were considered to be significantly different if P<0.05.
Results
Effects of somatostatin on the phosphorylation of the EGF/TGFα receptor in LNCaP cells
The presence of the EGF/TGFα receptor, previously reported in the literature (Davies & Eaton 1989) , was first confirmed in the clone of cells used in our laboratory. The identity of the 170 kDa band, expected to be the EGF/ TGFα receptor, was then validated by autoradiography of the immunoprecipitated labeled phosphoproteins using a specific monoclonal antibody raised against the EGF/ TGFα receptor. This result is presented in Fig. 1A . The phosphorylation levels of the EGF/TGFα receptor, evaluated by measuring the incorporation of [ 32 P]orthophosphate into TCA-precipitated samples, is shown in Fig. 1B . Treatment of LNCaP cells with somatostatin (S) for 45 min caused a significant decrease in the incorporation of the radiolabeled compound as compared with control cells (C). By contrast, cells treated with CM and somatostatin in combination (CM+S) or TGFα and somatostatin (TGFα+S) were able to overcome the effect of the hormone, showing levels of phosphorylation comparable to those of CM and TGFα alone. Cells treated with either TGFα or CM alone showed levels of phosphorylation not significantly different from control. In order to rule out the possibility that the decrease in the phosphorylation of the EGF/TGFα receptor observed after treatment with somatostatin might be the consequence of a decrease in the number of cells cultured (and, therefore, in the amount of the receptor present), the concentrations of total constitutive proteins and the number of cells were measured. No significant changes in either parameter were detected at the end of the 45 min incubation period (data not shown).
Effect of somatostatin on PTP activity in LNCaP cells
Somatostatin did not appear to exert a direct activation of PTP activity in LNCaP cells at any of the concentrations tested. In particular, 1 nM somatostatin -a dose previously shown to inhibit cell proliferation (Brevini et al. 1993) , as well as the phosphorylation of the EGF/TGFα receptor in LNCaP cells (see Fig. 1 ) -did not induce any significant variations in PTP activity between treated and control cells. In contrast, vanadate (50 µM), which is known to be an inhibitor of PTP, and was therefore used as a control, significantly reduced PTP activity in LNCaP cells (Fig. 2) .
Effect of somatostatin on the secretion of TGFα by LNCaP cells
The profile of the total proteins secreted by LNCaP cells, stained with Coomassie Brilliant Blue as previously described (Brevini et al. 1993) , is shown in Fig. 3 , lane A. The analysis of the same proteins blotted and tested with a specific anti-TGFα antibody (lane B) indicated the presence of a 60 kDa immunoreactive TGFα-like peptide. The secretion of this peptide was markedly decreased in cells treated with somatostatin (lane C). However, this TGFα-like peptide shows a higher molecular weight than the 5.5 kDa purified product (Fig. 3, lane B) . The possibility that this growth factor might be released by LNCaP cells in a glycosylated form was considered as one of the possible explanations for its high molecular weight (see also Discussion). A major glycosylated product was identified at the molecular weight corresponding to 60 kDa (Fig. 3, lanes D and E) , where proteins were blotted and stained for the presence of glycoresidues. Figure 4 shows the results obtained after performing reverse transcription (RT)-nested PCR for the presence of transcripts coding for TGFα in total RNA extracted from LNCaP cells. Amplified products were analyzed by 2% agarose gel electrophoresis in TAE buffer and demonstrated a cDNA fragment corresponding to the predicted size of the TGFα product, 237 bp (Fig. 4, lane A) .
Expression of TGFα mRNA in LNCaP cells
Promega pGEM was used as a standard (lane B)
. No amplified products were detected when the AMV reverse transcriptase was omitted from the first strand cDNA synthesis reaction prior to PCR (lane C). RNA extracted from the rat salivary glands was used as a positive control and included in all experiments; it produced the predicted 237 bp band (lane D).
Effect of somatostatin-treated LNCaP cell CM on LNCaP cell proliferation
The effect exerted by the secretory products released by LNCaP cells on the proliferation of LNCaP cells is shown in Fig. 5 . The addition of untreated LNCaP cell CM (5 µg total secreted proteins) to LNCaP cells resulted in a potent mitogenic effect, with a significant increase in the incorporation of [ 3 H]thymidine (CM) vs control LNCaP cells cultured in serum-free medium (C). Interestingly, when added to somatostatin-treated cells (CM+S), LNCaP cell CM was able to overcome the antiproliferative effect exerted by the hormone (S). Similarly, the addition of TGFα (10 ng/ml) significantly increased the mitogenic response in LNCaP cells (TGFα) and was able to counteract the inhibitory action exerted by somatostatin (TGFα+S). 
Discussion
The results presented in this study demonstrate that: (a) somatostatin interferes with the levels of phosphorylation of the EGF/TGFα receptor in LNCaP cells; the effect observed is induced by the same concentration of somatostatin (1 nM) previously shown to exert the most potent inhibitory action on the proliferation of LNCaP cells (Brevini et al. 1993) ; (b) somatostatin does not appear to activate PTPs directly; (c) somatostatin has the ability to reduce the release of TGFα produced by LNCaP cells which exert a mitogenic effect on the LNCaP cells themselves.
The presence of a functional EGF/TGFα receptor in LNCaP cells, demonstrated in the present paper, is consistent with the observation that this cell line possesses specific binding sites for EGF/TGFα (Fiorelli et al. 1989 , Ching et al. 1993 . Consistently, receptors for EGF/TGFα have also been shown in the normal prostate of rats and humans, as well as in benign hyperplasic prostatic tissues (Ching et al. 1993) . In addition, LNCaP cells express TGFα mRNA which is translated into a locally produced and secreted peptide. The simultaneous expression of the EGF/TGFα receptor and of one of its ligands (the endogenous TGFα), favors the presence of an autocrine/paracrine growth stimulatory loop in these cells, a result in line with other reports (Ching et al. 1993 , Limonta et al. 1994 ). In agreement with such an hypothesis, the addition of TGFα to LNCaP cells cultured in fetal calf serum (FCS), which is rich in growth factors, does not significantly increase the phosphorylation of the EGF/TGFα receptor (see Fig. 1 ); this may possibly be explained by assuming that the receptor is already activated by both the exogenous and endogenous growth factors. In contrast, when LNCaP cells are cultured in serum-free medium devoid of any growth factors, the addition of exogenous TGFα is able to induce a significant increase in cell proliferation (see Fig. 5 ). The observation that somatostatin interferes with the phosphorylation of the EGF/TGFα receptor in LNCaP cells suggests that somatostatin may inhibit the growth of prostatic cancer cells by interfering with actions mediated by the EGF/TGFα receptor and/or by its ligand. This is in line with the findings by this and other laboratories which have shown the involvement of tyrosine phosphorylation processess in the control of proliferation exerted by somatostatin in different tumoral cell lines (Liebow et al. 1991 , Pan et al. 1992 , Brevini et al. 1993 .
The interaction of somatostatin with phosphorylation pathways does not seem to involve a direct activation of specific membrane PTP in LNCaP cells (see Fig. 2 ). Similarly the involvement of cytosolic PTP, described in other models (Lopez et al. 1997 ) appears very unlikely, since experiments which we carried out in order to elucidate this point gave no indication of cytosolic PTP activation in response to somatostatin in LNCaP cells (data not shown). In both cell compartments, somatostatin was unable to modify PTP activity in this cell line, at least in the experimental conditions and with the methodology used in our laboratory. Therefore, the possibility that somatostatin might affect the activation of the EGF/TGFα receptor (and thus its phosphorylation) indirectly, i.e. possibly interfering with the secretion of one of its ligands, TGFα, has been considered. The present experiments confirm that a TGFα-like peptide is produced and secreted into the culture medium by LNCaP cells. This result is consistent with previous findings, showing the presence of TGFα immunoreactivity in LNCaP cell CM (Connolly & Rose 1990 , Ching et al. 1993 , and with the data of the RT/PCR studies presented here, indicating the expression of TGFα mRNA in LNCaP cells. Furthermore, the release of such a peptide is markedly decreased by the addition of somatostatin to the culture medium. Taken together, these observations would suggest that somatostatin may be able to reduce the secretion of factors involved in the phosphorylation process of the EGF/TGFα receptor. This antisecretory effect might represent one of the causes for decreased activation of the receptor, resulting, eventually, in the inhibition of LNCaP cell growth.
The present data indicate that TGFα immunoreactivity is located in the 60 kDa region, suggesting that such a factor is secreted by LNCaP cells in a molecular weight form higher than the 5.5 kDa purified product which has never been detected within the proteins secreted by LNCaP cells (Brevini et al. 1993) . Several hypotheses may be put forward to explain this observation: the secreted factor could represent either a precursor molecule or an oligomeric form of the 5.5 kDa species; it might be aggregated to a carrier protein; or finally, it might be glycosylated. In the present experiments, only the last possibility has been validated, showing a major glycosylated residue at the molecular weight corresponding to that identified with the TGFα-like peptide. Further studies are in progress to gain a better understanding of this observation. Indeed, secreted TGFα proteins displaying heterogeneity in molecular weight have been described previously (Marquardt et al. 1983 , Connolly & Rose 1990 , and may depend on differences in cleavage and post-translational modifications of the precursor in the various experimental models considered. Furthermore, recent observations describe an intriguing correlation between the presence of high molecular weight forms of TGFα and the occurrence of malignant phenotypes in prostate cancer (Ware et al. 1996) .
It is of interest that LNCaP cell CM is able to significantly increase the growth of LNCaP cells. When CM is added to somatostatin-treated cells, it appears to overcome the growth inhibitory effect of the hormone. Similarly, the addition of TGFα is able to raise the proliferation of somatostatin-treated cells back to levels comparable to those of TGFα alone. These findings give support to the results related to the effect of somatostatin on the phosphorylation levels of the EGF/TGFα receptor (see Fig. 1 ).
The biological actions of somatostatin are known to be mediated through specific high-affinity receptors (Reisine & Bell 1995) . Whether the observations reported in the present paper may be ascribed to any of the known receptor subtypes is yet to be elucidated, since the presence of these receptors in LNCaP cells is still debated. Work is in progress in our laboratory to clarify this point. Anyhow, the mechanism of somatostatin antiproliferative action is largely unknown and the involvement of multiple intracellular signaling pathways may be postulated. Dephosphorylation of the tyrosine kinases of some growth factor receptors, resulting in the inhibition of receptor tyrosine kinase-mediated signals, has been suggested as one of the possible mechanisms (Reisine & Bell 1995 , Yoshitomi et al. 1997 . The results presented in this paper appear to be in line with this hypothesis.
